Bagsværd, Denmark, 11 February 2021 – Novo Nordisk
A/S has filed its Annual Report 2020 on Form 20-F for the financial
year 2020 with the US Securities and Exchange Commission (SEC),
incorporating by reference parts of the Novo Nordisk A/S Annual Report
2020. The reports are available at the SEC's website, www.sec.gov, as
well as on novonordisk.com.
Shareholders may receive a hardcopy of Novo Nordisk’s completed audited financial statements free of charge upon request to firstname.lastname@example.org.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com , Facebook, Twitter , LinkedIn , YouTube .
|Anne Margrethe Hauge||+45 3079 email@example.com|
|Michael Bachner (US)||+1 609 664 firstname.lastname@example.org|
|Daniel Muusmann Bohsen||+45 3075 email@example.com|
|Valdemar Borum Svarrer||+45 3079 firstname.lastname@example.org|
|Ann Søndermølle Rendbæk||+45 3075 email@example.com|
|Mark Joseph Root||+45 3079 firstname.lastname@example.org|
|Kristoffer Due Berg (US)||+1 609 235 email@example.com|